GSK announces cap of $35 per month on U.S. patient out-of …
GSK today announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease (COPD) medicines,* the most prescribed portfolio of inhalers in the U.S. GSK is taking this action as part of its longstanding commitment to improving access to respiratory ...
Products - GSK US
Below you can find the full A-Z list of our products available in the United States.
Respiratory - GSK US
With over 50 years in respiratory care, GSK is committed to helping patients breathe better by continuously redefining treatment for COPD and asthma. We are driven by our commitment to research and uniting innovative science and technology to help people with these respiratory conditions live more comfortably.
FDA approves Trelegy Ellipta as the first once-daily single ... - GSK
The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US.
US FDA accepts GSK’s submission for the use of Nucala …
2024年12月9日 · GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the regulatory review process to obtain a new indication for the use of Nucala (mepolizumab), as an add-on maintenance treatment for patients with chronic obstructive pulmonary disease …
GSK submits filing to FDA for Trelegy Ellipta use in patients with ...
2019年10月2日 · GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI), for the ...
Press releases | GSK US
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma Regulatory designation based on promising early data in this rare bone cancer.
Home | GSK US
January 07 2025 GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma December 16 2024 Jemperli (dostarlimab-gxly) receives US FDA ...
GSK announces major renewable energy investment and low …
2021年9月20日 · A new lower greenhouse gas propellant is now in pre-clinical assessment, with the potential to reduce greenhouse gas emissions from its inhalers by 90%. 45% of GSK’s carbon emissions come from asthma patients using our metered dose inhalers for rescue medication.
once-daily, single inhaler triple therapy for COPD. It is comprised of fluticasone furoate (FF), an inhaled corticosteroid (ICS); umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA); and vilanterol (VI), a long-acting beta2-adrenergic agonist (LABA), delivered in a single daily inhalation from GSK’s Ellipta inhaler.5